Sanctuary Advisors LLC Has $197,000 Stock Position in Repligen Co. (NASDAQ:RGEN)

Sanctuary Advisors LLC decreased its stake in shares of Repligen Co. (NASDAQ:RGEN) by 16.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,368 shares of the biotechnology company’s stock after selling 268 shares during the period. Sanctuary Advisors LLC’s holdings in Repligen were worth $197,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Resources Management Corp CT ADV bought a new position in Repligen during the 3rd quarter worth about $37,000. Quarry LP boosted its position in shares of Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after buying an additional 239 shares during the period. UMB Bank n.a. grew its holdings in shares of Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after buying an additional 110 shares in the last quarter. GAMMA Investing LLC raised its position in Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 90 shares during the last quarter. Finally, Quest Partners LLC bought a new stake in Repligen in the 3rd quarter valued at approximately $166,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Up 1.8 %

NASDAQ RGEN opened at $157.67 on Thursday. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The company has a market cap of $8.83 billion, a price-to-earnings ratio of -309.16, a PEG ratio of 4.54 and a beta of 0.99. The company has a 50 day moving average of $156.74 and a 200-day moving average of $148.54. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $203.13.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. On average, equities research analysts expect that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

RGEN has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and set a $180.00 price target on shares of Repligen in a research note on Friday, February 21st. Royal Bank of Canada raised their target price on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, February 21st. Wolfe Research began coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating on the stock. JPMorgan Chase & Co. increased their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Finally, Canaccord Genuity Group lifted their target price on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $181.00.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.